Octarine Bio
Synthetic biology company developing cannabinoid and psilocybin derivatives.
5
Funding Rounds
$10.4m
Money raised
Overview
Synthetic biology company developing cannabinoid and psilocybin derivatives.
-
Website:
- Business model: B2B
- Headquarters: Copenhagen
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company Octarine Bio has raised a total of $10.4m in funding over 5 rounds.
Key Insights:
- Octarine Bio November 2023 Series A Funding Round: $4.6m
- Octarine Bio November 2023 Series A Funding Round: $4.6m
- Octarine Bio March 2021 Seed Funding Round: $1.2m
Octarine Bio November 2023 Series A Funding Round
$4.6m
Octarine Bio November 2023 Series A Funding Round
$4.6m
Octarine Bio March 2021 Seed Funding Round
$1.2m
Industries
Octarine Bio is active in the following industries: